[1] CAO MM, CHEN WQ.Interpretation on the global cancer statistics of GLOBOCAN 2020[J]. Chinese Journal of the Frontiers of Medical Science (Electronic Version)(中国医学前沿杂志电子版), 2021, 13(3): 63-69. [2] National Cancer Center, Prostate Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of prostate cancer in China (2022 edition)[J]. Chin J Oncol(中华肿瘤杂志), 2022, 44(10): 1011-1016. [3] CHONG YL, MENG Y, XIA XM.Efficacy and safety of abiraterone acetate in the treatment of castration-resistant prostate cancer: a meta-analysis[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2022, 22(3): 276-283. [4] MOSES MA, KIM YS, RIVERA-MARQUEZ GM, et al.Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer[J]. Cancer Research, 2018, 78(14): 4022-4035. [5] LI G, AN RH.Recent advances in diagnosis and treatment of metastatic hormone-sensitive prostate cancers[J]. Journal of Clinical and Pathological Research(临床与病理杂志), 2021, 41(10): 2468-2475. [6] WEN SJ, CAI Y, CHEN MF.Clinical analysis of goserelin combined with abiraterone neoadjuvant therapy for locally advanced prostate cancer(report of 31 cases)[J]. Journal of Clinical Urology(临床泌尿外科杂志), 2022, 37(10): 735-738. [7] DE BONO JS, LOGOTHETIS CJ, MOLINA A, et al.Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med, 2011, 364(21): 1995-2005. [8] RATHKOPF DE, SMITH MR, DE BONO JS, et al.Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)[J]. Eur Urol, 2014, 66(5): 815-825. [9] ZHANG KW, REIMERS MA, CALAWAY AC, et al.Cardiovascular events in men with prostate cancer receiving hormone therapy: an analysis of the FDA Adverse Event Reporting System (FAERS)[J]. J Urol, 2021, 206(3): 613-622. [10] MOORE DC, RINGLEY JT.Rhabdomyolysis with abiraterone exposure: a brief review of the Food and Drug Administration Adverse Event Reporting System (FAERS)[J]. Ann Pharmacother, 2018, 52(11): 1160-1161. [11] WU L, INGLE T, LIU Z, et al.Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA[J]. BMC Bioinformatics, 2019, 20(Suppl 2):97. [12] BATE A, EVANS SJ.Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf, 2009, 18(6): 427-436. [13] KHALEEL MA, KHAN AH, GHADZI SMS, et al.A standardized dataset of a spontaneous adverse event reporting system[J]. Healthcare (Basel), 2022, 10(3): 420. [14] FDA. ZYTIGA™ (abiraterone acetate) Tablets For Oral Administration Initial U.S. Approval -2011[EB/OL]. [2023-06-08]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf. [15] WEN R, MA K, HUANG XH, et al . Research progress of biomarkers related to early diagnosis of prostate cancer[J]. Inner Mongolia Medical Journal(内蒙古医学杂志), 2022, 54(7): 821-824, 828. [16] NORDENSTROM A, LAJIC S, FALHAMMAR H.Clinical outcomes in 21-hydroxylase deficiency[J]. Curr Opin Endocrinol Diabetes Obes, 2021, 28(3): 318-324. [17] BONNEFOI H, GRELLETY T, TREDAN O, et al.A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)[J]. Ann Oncol, 2016, 27(5): 812-818. [18] O'SHAUGHNESSY J, CAMPONE M, BRAIN E, et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer[J]. Ann Oncol, 2016, 27(1): 106-113. [19] GERRATANA L, BASILE D, BUONO G, et al.Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype[J]. Cancer Treat Rev, 2018, 68: 102-110. [20] HE J, CHEN WQ, LI N, et al.China guideline for the screening and early detection of prostate cancer(2022,Beijing)[J]. China Cancer(中国肿瘤), 2022, 31(1): 1-30. [21] WANG ZY, ZHANG ZW.Severe hypokalemia induced by abiraterone: one case report[J].Chinese Journal of Multiple Organ Diseases in the Elderly(中华老年多器官疾病杂志), 2021, 20(8): 621-622. [22] RYAN CJ, SMITH MR, FONG L, et al.Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with Castration-Resistant prostate cancer who received prior ketoconazole therapy[J]. J Clin Oncol, 2010, 28(9): 1481-1488. [23] BRETAGNE M, LEBRUN-VIGNES B, PARIENTE A, et al.Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study[J]. Arch Cardiovasc Dis, 2020, 113(1): 9-21. [24] CHENG HG, LI XW, GOU X.Selection of new type endocrine drugs for special population with prostate cancer[J]. Chongqing Medicine(重庆医学), 2022, 51(16): 2866-2869. [25] LI JW, WANG YH, ZHAO J, et al.The safety of abiraterone in the treatment of prostate cancer: a Meta-analysis[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2018, 23(3): 239-245. [26] YUMIBA S, KOMORI K, IWANISHI T, et al.A case of fulminant hepatitis after administration of abiraterone acetate[J]. Hinyokika Kiyo, 2017, 63(11): 479-482. [27] WU L, WEI L. One case of severe heart failure caused by abiraterone[J]. Journal of Contemporary Urologic and Reproductive Oncology(现代泌尿生殖肿瘤杂志), 2022, 14(3): 175, 183. [28] LEE DH, MONEY DB, DESHPANDE A, et al.A case of abiraterone-related hypokalemia leading to torsades de pointes and cardiac arrest[J]. Cureus, 2022, 14(3): e23678. [29] AY C, PABINGER I, COHEN AT.Cancer-associated venous thromboembolism: Burden, mechanisms, and management[J].Thromb Haemost, 2017, 117(2): 219-230. [30] HARITA K, HARA Y, MUROHASHI K, et al.A case of drug-induced lung injury induced by abiraterone acetate linked to serum heme oxygenase-1[J]. AJRS, 2020, 9: 141-146. [31] SKEOCH S, WEATHERLEY N, SWIFT AJ, et al.Drug-induced interstitial lung disease: a systematic review[J]. J Clin Med, 2018, 7(10): 356. [32] WU B, SHEN P, YIN X, et al.Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System[J]. Br J Clin Pharmacol, 2023, 89(2): 440-448. [33] MORALES X, GARNICA D, ISAZA D, et al.Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation[J]. BMC Cardiovasc Disord, 2021, 21(1): 136. [34] FAN FS, YANG CF.Leukoerythroblastosis in castration-resistant prostate cancer: a clue to diffuse bone marrow carcinomatosis[J]. Clin Pract, 2019, 9(2): 1124. [35] SHAMDAS GJ, AHMANN FR, MATZNER MB, et al.Leukoerythroblastic anemia in metastatic prostate cancer.Clinical and prognostic significance in patients with hormone-refractory disease[J]. Cancer, 1993, 71: 3594-3600. [36] YUH DY, CHANG TH, HUANG RY, et al.The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan[J]. J Dent, 2014, 42: 1343-1352. [37] SAAD F, SHORE N, VAN POPPEL H, et al.Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302[J]. Eur Urol, 2015, 68(4): 570-577. [38] FENG ZQ, AN JG, ZHANG Y, et al.Surgical treatment of severe medication-related osteonecrosis of the jaw[J]. West China Journal of Stomatology(华西口腔医学杂志), 2023, 41(1): 43-51. [39] MA YH, WANG Q, LI J, et al.Progress of bisphosphonate related osteonecrosis of the jaws[J]. Chinese Journal of Osteoporosis and Bone Mineral Research(中华骨质疏松和骨矿盐疾病杂志), 2021, 14(5): 544-552. [40] SHANG PH, ZHAN SY.Application of data mining in detection and analysis of adverse drug reaction signals(Part II)[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2009, 6(3): 187-190. |